0613 Effects of Pitolisant on Nighttime Sleep [PDF]
Sleep, 2019 Ulf Kallweit, Annika Triller
openalex +2 more sources
Effects of Histamine H<sub>3</sub> Receptor Antagonist/Inverse Agonist Pitolisant on Temporal Prediction, Spatial Switching, and Spontaneous Locomotion in Mice. [PDF]
Neuropsychopharmacol RepThe histamine H3 receptor antagonist/inverse agonist pitolisant did not affect temporal prediction and spatial switching. ABSTRACT Histamine receptors contribute to a wide range of brain functions, including arousal, motivation, attention, and memory, but their causal involvement in switching behavior remains insufficiently understood.
Kaneko S, Hayashi K, Yamada K, Toda K.
europepmc +2 more sources
Effect of sleep apnoea interventions on multiple health outcomes: an umbrella review of meta-analyses of randomised controlled trialsResearch in context [PDF]
EClinicalMedicineSummary: Background: Obstructive sleep apnoea (OSA) is a prevalent chronic condition that is associated with cardiometabolic and neurocognitive complications.
Camille Figard +7 more
doaj +2 more sources
Indikationserweiterung für Pitolisant bei Narkolepsie
InFo Neurologie + PsychiatrieYvette Zwick
openalex +2 more sources
Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study [PDF]
Cicolin, Alessandro
core +2 more sources
Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort [PDF]
, 2022 Introduction Narcolepsy is a chronic and rare hypersomnia of central origin characterized by excessive daytime sleepiness and a complex array of symptoms as well as by several medical comorbidities.
Agostoni, Elio Clemente +28 more
core +5 more sources
Histamine H3 receptor antagonism modulates autism-like hyperactivity but not repetitive behaviors in BTBR T+Itpr3tf/J inbred mice [PDF]
, 2022 Background: Autism spectrum disorders (ASDs) are a group of neurodevelopmental conditions defined by behavioral deficits in social communication and interactions, mental inflexibility and repetitive behaviors.
Hutten, Lianda +2 more
core +1 more source
Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP A Randomized Trial [PDF]
, 2021 BACKGROUND: Excessive daytime sleepiness (EDS) in individuals with OSA syndrome persisting despite good adherence to CPAP is a disabling condition. Pitolisant is a selective histamine H3-receptor antagonist with wake-promoting effects. RESEARCH QUESTION:
Dauvilliers, Yves +5 more
core +1 more source
Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority metaanalytical approach
Drugs in Context, 2020 Aim: To assess the non-inferiority of pitolisant, a new compound for the relief of excessive daytime sleepiness (EDS) and cataplexy in narcolepsy, compared with modafinil.
Philippe Lehert, Cassandra Szoeke
doaj +1 more source
Scientific Reports, 2022 Histamine is a neurotransmitter that modulates neuronal activity and regulates various brain functions. Histamine H3 receptor (H3R) antagonists/inverse agonists enhance its release in most brain regions, including the cerebral cortex, which improves ...
Kyosuke Hirano +3 more
doaj +1 more source